Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 3/20 | 0.43 |
| ▸ | TACR1 | P25103 | 9/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26399605 | 1.00 | OPRL1 (0.43) | OPRL1CTSKTACR1CYP3A4CYP2D6 | |
| SCHEMBL5221681 | 0.89 | GPR119 (0.47) | CTSKTACR1HSD11B1 | |
| SCHEMBL5226606 | 0.89 | GPR119 (0.47) | CTSKTACR1HSD11B1 | |
| SCHEMBL5227765 | 0.89 | GPR119 (0.47) | CTSKTACR1HSD11B1 | |
| SCHEMBL12435283 | 0.82 | SIGMAR1 (0.48) | OPRL1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL26399598 | 0.82 | SIGMAR1 (0.48) | OPRL1TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1503863 | 0.79 | CTSK (0.50) | CTSKDPP4DPP7KCNH2CPB1 | |
| SCHEMBL1504080 | 0.79 | CTSK (0.50) | CTSKDPP4DPP7KCNH2CPB1 | |
| SCHEMBL5259400 | 0.77 | SMN1; SMN2 (0.50) | TACR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL4405607 | 0.77 | SMN1; SMN2 (0.50) | TACR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | OPRL1 18/4885CTSK 2199/4885TACR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.